Selectively altering microbiota for immune modulation
The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
1. A method for treating an infectious disease in a human patient, wherein the method comprises
(a) exposing a microbiota in the patient to a guided nuclease to selectively target the genome of cells of a first species in the microbiota using the guided nuclease, wherein the first species is a bacterial or archaeal species; and simultaneously or sequentially administering to the patient an effective amount of an immunotherapy; and
(b) allowing the guided nuclease to cut one or more target nucleotide sequences comprised by first cells of a first strain of the first species, thereby killing the first cells or reducing the growth thereof, whereby the proportion of the first cells comprised by the microbiota is reduced;
wherein
(c) the selective targeting avoids targeting second cells comprised by the microbiota, wherein the second cells are of a different strain or a different species from the first cells, wherein the second cells are probiotic, commensal or symbiotic with humans; and
(d) the reducing of the proportion of the first cells modulates immune cells in the patient, whereby the efficacy of the immunotherapy is enhanced for treatment of the infectious disease in the patient.
2. The method of claim 1 , wherein the infectious disease is selected from the group consisting of malaria, Human Immunodeficiency Virus (HIV) infection, tuberculosis infection, cholera, Salmonella typhimurium infection, Clostridium difficile infection, Bordetella pertussis infection or chlamydia infection.
3. The method of claim 1 , wherein the infectious disease is a viral infection or mediated by a viral infection.
4. The method of claim 1 , wherein the immunotherapy is a vaccine therapy.
5. The method of claim 4 , wherein the immunotherapy is a bacterial vaccine.
6. The method of claim 4 , wherein the immunotherapy is a viral vaccine.
7. The method of claim 4 , wherein the immunotherapy is a cancer vaccine.
8. The method of claim 3 , wherein the immunotherapy is an anti-retroviral therapy.
9. The method of claim 8 , wherein the immunotherapy is an HIV vaccine therapy.
10. The method of claim 1 , wherein the growth of the first cells is inhibited by at least 1000 times compared to the growth inhibition of the second cells 24 hours after exposing the first and second cells to the guided nuclease in an in vitro assay.
11. The method of claim 1 , wherein and the immune cells comprise cells selected from CD8 + cells, tumor infiltrating lymphocytes (TILs), CD4 + cells, T reg cells and memory cells.
12. The method of claim 1 , wherein the first species is a gram negative bacterial species.
13. The method of claim 1 , wherein the immune cells are upregulated or expanded in the patient.
14. The method of claim 1 , wherein the immune cells comprise memory cells selected from the group consisting of central memory T-cells (TCM), effector memory T-cells (TEM), stem cell memory cells (TSCM), and memory effector T-cells (Teff).
15. The method of claim 1 , wherein the immune cells comprise memory cells selected from the group consisting of CD45RO + CD62L + and CD25 + CD45RA − CD45RO + CD127 + cells.
16. The method of claim 1 , wherein the microbiota is a gut microbiota of the patient.
17. The method of claim 1 , wherein the immune cells comprise administered cells via adoptive cell therapy.
18. The method of claim 1 , wherein the guided nuclease is a Cas, Transcription activator-like effector nuclease (TALEN), meganuclease or zinc finger nuclease.
19. The method of claim 1 , wherein the efficacy of the immunotherapy is enhanced by upregulating T H 17 cells in the patient.
20. The method of claim 19 , wherein the T H 17 cells are endogenous cells of the patient.
21. The method of claim 1 , wherein the second cells have a 16s ribosomal RNA-encoding DNA sequence that is at least 80% identical to a 16s ribosomal RNA-encoding DNA sequence of the first cells.
22. The method of claim 1 , wherein the first cells and the second cells are comprised by a gut microbiota, skin microbiota, oral cavity microbiota, throat microbiota, hair microbiota, armpit microbiota, vaginal microbiota, rectal microbiota, anal microbiota, ocular microbiota, nasal microbiota, tongue microbiota, lung microbiota, liver microbiota, kidney microbiota, genital microbiota, penile microbiota, scrotal microbiota, mammary gland microbiota, ear microbiota, urethra microbiota, labial microbiota, organ microbiota or dental microbiota.